Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DMB-3111 and Trastuzumab in Healthy Volunteers
NCT02100917Phase 1Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Jan 2014
- Primary completion
- May 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMB-3111 in HER2-positive breast cancer and gastric cancer (GC) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve and Maximum Observed Serum Concentration. Started Jan 2014; status: completed.
02
Drugs
DMB-3111
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02100917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100917.